Loading...
XKRX
000520
Market cap148mUSD
Dec 05, Last price  
10,280.00KRW
1D
-1.53%
1Q
-8.54%
Jan 2017
178.28%
Name

Samil Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XKRX:000520 chart
P/E
—
P/S
0.99
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.01%
Rev. gr., 5y
12.65%
Revenues
219.70b
+11.89%
104,901,180,000125,514,432,000115,949,870,00098,333,934,00094,475,808,06091,444,317,23089,228,923,81085,460,672,86088,136,458,80096,758,065,72092,037,814,99094,599,866,210121,107,085,910122,998,992,150134,246,777,890179,676,108,240196,345,807,840219,699,586,000
Net income
-5.63b
L
5,539,820,0001,748,494,0007,063,831,0002,044,324,000-6,778,721,000-2,899,828,8807,930,032,140-11,189,534,420588,369,390886,602,990-1,266,565,050-8,562,748,000786,258,2901,340,563,620-5,346,662,650-28,287,0101,663,539,539-5,628,802,000
CFO
2.59b
-38.28%
6,661,030,000-6,611,789,000-10,154,470,000-8,748,445,000-4,556,635,0305,023,343,130-3,990,162,170-11,923,423,1202,919,997,1405,634,351,3103,791,492,000-2,621,621,62010,590,303,2807,774,731,5901,416,861,1504,153,916,6004,196,205,4392,589,902,000
Dividend
Dec 29, 202180 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of indispensable medicines in South Korea. It offers hepatic, gastrointestinal, vasodilator, antithrombotic, respiratory, skeletal muscle relaxants, circulatory, neurological, antibiotics, metabolic, antihistamines, immunosuppressive, hormone, anti-tumor, urinary, and ophthalmic drugs, as well as antipyretic, analgesic, and anti-inflammatory agents. The company also provides OTC products and sanitary aids. Samil Pharmaceutical Co.,Ltd was founded in 1947 and is headquartered in Seoul, South Korea.
URL
http://www.samil-pharm.com/
IPO date
May 29, 1985
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT